Kundig C - Search Results

1

Hyperbaric Oxygen Therapy versus placebo for post-concussion syndrome (HOT-POCS): A randomized, double-blinded controlled pilot study.

Wright B, Guilliod R, Thakur B, Kundig C, Morales J, Tessler J, Berry J, Zhang R, Bell KR, Pinto SM. Wright B, et al. Among authors: kundig c. Contemp Clin Trials Commun. 2023 Jun 20;34:101176. doi: 10.1016/j.conctc.2023.101176. eCollection 2023 Aug. Contemp Clin Trials Commun. 2023. PMID: 37416626 Free PMC article.

2

Drug resistance in Leishmania: similarities and differences to other organisms.

Papadopoulou B, Kündig C, Singh A, Ouellette M. Papadopoulou B, et al. Among authors: kundig c. Drug Resist Updat. 1998;1(4):266-78. doi: 10.1016/s1368-7646(98)80007-1. Drug Resist Updat. 1998. PMID: 16904409

3

Peptabody-EGF: a novel apoptosis inducer targeting ErbB1 receptor overexpressing cancer cells.

Fattah OM, Cloutier SM, Kündig C, Felber LM, Gygi CM, Jichlinski P, Leisinger HJ, Gauthier ER, Mach JP, Deperthes D. Fattah OM, et al. Among authors: kundig c. Int J Cancer. 2006 Nov 15;119(10):2455-63. doi: 10.1002/ijc.21541. Int J Cancer. 2006. PMID: 16858684 Free article.

4

Activation and enzymatic characterization of recombinant human kallikrein 8.

Kishi T, Cloutier SM, Kündig C, Deperthes D, Diamandis EP. Kishi T, et al. Among authors: kundig c. Biol Chem. 2006 Jun;387(6):723-31. doi: 10.1515/BC.2006.091. Biol Chem. 2006. PMID: 16800733 Free article.

5

Mutant recombinant serpins as highly specific inhibitors of human kallikrein 14.

Felber LM, Kündig C, Borgoño CA, Chagas JR, Tasinato A, Jichlinski P, Gygi CM, Leisinger HJ, Diamandis EP, Deperthes D, Cloutier SM. Felber LM, et al. Among authors: kundig c. FEBS J. 2006 Jun;273(11):2505-14. doi: 10.1111/j.1742-4658.2006.05257.x. FEBS J. 2006. PMID: 16704423 Free article.

6

Enzymatic profiling of human kallikrein 14 using phage-display substrate technology.

Felber LM, Borgoño CA, Cloutier SM, Kündig C, Kishi T, Ribeiro Chagas J, Jichlinski P, Gygi CM, Leisinger HJ, Diamandis EP, Deperthes D. Felber LM, et al. Among authors: kundig c. Biol Chem. 2005 Mar;386(3):291-8. doi: 10.1515/BC.2005.035. Biol Chem. 2005. PMID: 15843175

7

Profiling of proteolytic activities secreted by cancer cells using phage display substrate technology.

Cloutier SM, Kündig C, Gygi CM, Jichlinski P, Leisinger HJ, Deperthes D. Cloutier SM, et al. Among authors: kundig c. Tumour Biol. 2004 Jan-Apr;25(1-2):24-30. doi: 10.1159/000077720. Tumour Biol. 2004. PMID: 15192309

8

Evaluation of the CFP-substrate-YFP system for protease studies: advantages and limitations.

Felber LM, Cloutier SM, Kündig C, Kishi T, Brossard V, Jichlinski P, Leisinger HJ, Deperthes D. Felber LM, et al. Among authors: kundig c. Biotechniques. 2004 May;36(5):878-85. doi: 10.2144/04365PT04. Biotechniques. 2004. PMID: 15152609 Free article.

9

Inactivation of the Leishmania tarentolae pterin transporter (BT1) and reductase (PTR1) genes leads to viable parasites with changes in folate metabolism and hypersensitivity to the antifolate methotrexate.

El Fadili A, Kündig C, Roy G, Ouellette M. El Fadili A, et al. Among authors: kundig c. J Biol Chem. 2004 Apr 30;279(18):18575-82. doi: 10.1074/jbc.M400652200. Epub 2004 Feb 23. J Biol Chem. 2004. PMID: 14981076 Free article.

10

Development of recombinant inhibitors specific to human kallikrein 2 using phage-display selected substrates.

Cloutier SM, Kündig C, Felber LM, Fattah OM, Chagas JR, Gygi CM, Jichlinski P, Leisinger HJ, Deperthes D. Cloutier SM, et al. Among authors: kundig c. Eur J Biochem. 2004 Feb;271(3):607-13. doi: 10.1111/j.1432-1033.2003.03963.x. Eur J Biochem. 2004. PMID: 14728688 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

25 results

Search Page